CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 122,182	$ 137,547	$ 537,840
Cost of revenues	29,614	27,727	114,867
Gross profit	92,568	109,820	422,973
Operating costs and expenses:
Research, development and clinical studies	59,704	42,234	206,085
Sales and marketing	51,169	37,884	173,658
General and administrative	41,944	30,508	132,753
Total operating costs and expenses	152,817	110,626	512,496
Operating income (loss)	(60,249)	(806)	(89,523)
Financial income (expenses), net	9,169	(1,709)	7,677
Income (loss) before income tax	(51,080)	(2,515)	(81,846)
Income tax	1,981	2,132	10,688
Net income (loss)	$ (53,061)	$ (4,647)	$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.50)	$ (0.04)	$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	105,667,072	104,186,120	104,660,476
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.50)	$ (0.04)	$ (0.88)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	105,667,072	104,186,120	104,660,476